Hormonal
Continuous administration of GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produces significant weight loss (6-22%) and cardiovascular risk reduction, but discontinuation leads to rapid weight regain and loss of therapeutic benefits.
Obesity pharmacotherapy with GLP-1/GIP agonists is highly effective for weight loss and cardiovascular health, but it is not a 'cure' with a fixed end date. You must continue the medication long-term to maintain weight loss; stopping leads to rapid regain. Discuss with your doctor whether the benefits of continuous therapy outweigh the burden of daily/weekly injections and potential side effects.
Die positiven Effekte werden durch ein Absetzen der Therapie meist nivelliert. [...] Nach Abchluss der 68-wöchigen Interventionen wurde in der STEP 1-Verlängerungsstudie für insgesamt 120 Wochen ohne fortgesetzte Therapie weiter nachbeobachtet. Am Ende des Studienzeitraums waren sämtliche therapeutischen Effekte nivelliert.
Why this rating
Based on multiple high-quality, placebo-controlled, randomized trials (SCALE, STEP, SURMOUNT programs) with large sample sizes.
Source
Peptidhormonanaloga basierte medikamentöse Adipositastherapie ist effektiv
M. Azhar Hussain et al. · Die Chirurgie · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →